iRhythm Holdings, Inc. IRTC
iRhythm is a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. 10-K, Item 1
- Employees
- 2,400
- Headquarters
- San Francisco, CA
- CEO
- Quentin S. Blackford
- Next results
- around Feb 18, 2027
IRTC among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
10 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 19, 2026 against Feb 20, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
2facts worth reading about the other 9 checks found nothing to note
-
Inventory growing faster than revenueInventory +54.1% ($14.0M to $21.6M) vs revenue +26.2% ($591.8M to $747.1M), +27.9 pts apart
-
Auditor change8-K item 4.01 (change in certifying accountant) filed Apr 1, 2026
-
Receivables -5.3% ($79.9M to $75.7M) vs revenue +26.2% ($591.8M to $747.1M), -31.5 pts apart
8 more checks with nothing to note
-
Cash from operations $80.9M vs net income −$44.6M (FY ending Dec 31, 2025)
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Contractual Allowance - Contracted Third-Party Payors
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
10 paragraphs in Risk Factors that were not in the 10-K filed Feb 20, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
We also regularly evaluate a variety of other potential strategic transactions, including equity and other investments and strategic alliances. Equity and other investments and strategic alliances pose additional risks, as we could share ownership and, in some cases, management responsibilities with one or more other parties whose…
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
Healthcare laws and regulations, and interpretations of the same, change frequently and may change significantly in the future. We may not be able to adapt our operations to address every new regulation or interpretation, and new regulations or interpretations may adversely affect our business. For example, FDA has taken novel steps in…
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
As a public company, we are subject to certain reporting requirements, including those under the Sarbanes-Oxley Act, which requires, among other things, that we maintain effective internal control over financial reporting and disclosure controls and procedures. In order to maintain and improve the effectiveness of our internal controls…
-
Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
In addition, the BIOSECURE Act was signed into law in December 2025 as part of the National Defense Authorization Act restricting U.S. federal contracts and funding for companies using biotech equipment or services from "biotechnology companies of concern" ("BCCs"), to curb national security risks. A phased rollout includes publishing…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $410.9M | $492.7M | $591.8M | $747.1M |
| Net income | −$116.2M | −$123.4M | −$113.3M | −$44.6M |
| Operating cash flow | −$23.0M | −$50.1M | $3.4M | $80.9M |
| Free cash flow | −$52.8M | −$90.5M | −$30.6M | $34.5M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$747.1M ▲ 26.2% in FY2025−$44.6M in FY2025$34.5M in FY2025
Recent filings
4 filings in the last 30 days · SEC EDGAR
-
8-KNov 13, 2026Director or officer change 8-K item 5.02
-
8-KNov 12, 2026Regulation FD disclosure, Other events 8-K items 7.01, 8.01
-
8-KNov 5, 2026Quarterly results 8-K item 2.02
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
iRhythm Holdings, Inc., San Francisco, CA · from the 10-K filed Feb 19, 2026
iRhythm is a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Our principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that we believe allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology.
- Headquarters
- San Francisco, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 5, 2026
Employees, at the top of the page: "As of December 31, 2025, we had approximately 2,400 employees globally" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 19, 2026 (open at SEC), compared with the 10-K filed Feb 20, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IRTC/export.csv") into a cell.